Unknown

Dataset Information

0

Transcriptional diversity of long-term glioblastoma survivors.


ABSTRACT: Glioblastoma (GBM) is a highly aggressive type of glioma with poor prognosis. However, a small number of patients live much longer than the median survival. A better understanding of these long-term survivors (LTSs) may provide important insight into the biology of GBM.We identified 7 patients with GBM, treated at Memorial Sloan-Kettering Cancer Center (MSKCC), with survival >48 months. We characterized the transcriptome of each patient and determined rates of MGMT promoter methylation and IDH1 and IDH2 mutational status. We identified LTSs in 2 independent cohorts (The Cancer Genome Atlas [TCGA] and NCI Repository for Molecular Brain Neoplasia Data [REMBRANDT]) and analyzed the transcriptomal characteristics of these LTSs.The median overall survival of our cohort was 62.5 months. LTSs were distributed between the proneural (n = 2), neural (n = 2), classical (n = 2), and mesenchymal (n = 1) subtypes. Similarly, LTS in the TCGA and REMBRANDT cohorts demonstrated diverse transcriptomal subclassification identities. The majority of the MSKCC LTSs (71%) were found to have methylation of the MGMT promoter. None of the patients had an IDH1 or IDH2 mutation, and IDH mutation occurred in a minority of the TCGA LTSs as well. A set of 60 genes was found to be differentially expressed in the MSKCC and TCGA LTSs.While IDH mutant proneural tumors impart a better prognosis in the short-term, survival beyond 4 years does not require IDH mutation and is not dictated by a single transcriptional subclass. In contrast, MGMT methylation continues to have strong prognostic value for survival beyond 4 years. These findings have substantial impact for understanding GBM biology and progression.

SUBMITTER: Gerber NK 

PROVIDER: S-EPMC4136896 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Background</h4>Glioblastoma (GBM) is a highly aggressive type of glioma with poor prognosis. However, a small number of patients live much longer than the median survival. A better understanding of these long-term survivors (LTSs) may provide important insight into the biology of GBM.<h4>Methods</h4>We identified 7 patients with GBM, treated at Memorial Sloan-Kettering Cancer Center (MSKCC), with survival >48 months. We characterized the transcriptome of each patient and determined rates of  ...[more]

Similar Datasets

2014-05-02 | E-GEOD-54077 | biostudies-arrayexpress
2014-05-02 | GSE54077 | GEO
| S-ECPF-GEOD-54077 | biostudies-other
| S-EPMC3592900 | biostudies-other
| S-EPMC6827834 | biostudies-literature
| S-EPMC10838123 | biostudies-literature
| S-EPMC10800987 | biostudies-literature
| S-EPMC8155513 | biostudies-literature
| S-EPMC8713760 | biostudies-literature
| S-EPMC3675853 | biostudies-other